Oncologists discuss long-term ibrutinib use, cardiovascular risks with BTK inhibitors, and emerging fixed-duration acalabrutinib-venetoclax therapy in CLL.
Advertisement
Advertisement
Trending on Targeted Onc
1
Dr Chauhan on DLL3 Expression and Obrixtamig Outcomes in DAREON-7
2
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
3
Phase 3 Results Point to a Path Forward for Cancer Vaccines
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5